VisionCare Receives Health Canada License for Telescope Prosthesis for End-Stage AMD

By
SARATOGA, Calif.— VisionCare Ophthalmic Technologies, developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced that it has received a Health Canada Medical Device License to market the Implantable Miniature Telescope in Canada. The telescope implant is an integral component of a new patient care program called CentraSight, which has been developed to improve vision and quality of life in patients with end-stage age-related macular degeneration (AMD), the most advanced form of AMD. Eligible patients must meet age, vision and cornea health requirements.

“The grant of the license from Health Canada to market our implantable telescope in the Canadian market is an important step forward," said Allen W. Hill, VisionCare's CEO. "Our company is moving forward both with the ophthalmic community and reimbursement authorities as we prepare for market introduction. We are excited to have the opportunity to provide.